

**ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES**  
**VACCINES FOR CHILDREN PROGRAM**  
**VACCINES TO PREVENT HUMAN PAPILLOMAVIRUS**

*The purpose of this resolution is to: allow routine use and catch up of the quadrivalent HPV vaccine for VFC-eligible males, 9 through 18 years old, and to streamline the resolution through the use of links to published documents.*

VFC Resolution 10/09-1 is repealed and replaced by the following:

**Eligible Groups**

Gender and Age	Bivalent HPV vaccine	Quadrivalent HPV vaccine
Females, 9 through 18 years	Eligible	Eligible
Males, 9 through 18 years	Not eligible	Eligible

**Recommended schedule**

A 3-dose series for HPV vaccine is recommended for females and males at age 11 or 12 years old with the following schedule: the quadrivalent HPV vaccine (for use in females and males) or the bivalent HPV vaccine (for use in females) is to be administered in a 3-dose schedule. The second dose should be administered 1 to 2 months after the first dose and the third dose should be administered 6 months after the first dose.

The HPV vaccines series should be completed with the same HPV vaccine product whenever possible.

*Catch-up vaccination*

Vaccination is recommended for females and males 13 through 18 years of age who have not been previously vaccinated or who have not completed the full series.

*Other vaccination*

Eligible females and males as young as 9 years old may be vaccinated.

*Interrupted vaccination schedule*

If the vaccine schedule is interrupted for either the quadrivalent or bivalent HPV vaccine, the vaccine series does not need to be restarted. If the series is interrupted after the first dose, the second dose should be administered as soon as possible, and the second and third doses should be separated by an interval of at least 12 weeks with a minimum interval of 24 weeks between the first and third doses. If only the third dose is delayed, it should be administered as soon as possible.

## **Dosage Intervals**

The minimum interval between the first and second doses of vaccine is 4 weeks and the minimum recommended interval between the second and third dose of vaccine is 12 weeks. The minimum interval between the first and third dose is 24 weeks. Inadequate doses of HPV vaccine or vaccine doses received after a shorter-than-recommended dosing interval should be readministered.

## **Recommended dosage**

Recommended dosage for the bivalent and quadrivalent HPV vaccines can be found in the package inserts available at:

<http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833>

## **Precautions and contraindications**

*Quadrivalent HPV vaccine:*

Refer to ACIP recommendation at:

<http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5602a1.htm>

[http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a5.htm?s\\_cid=mm5920a5\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a5.htm?s_cid=mm5920a5_e)

*Bivalent HPV vaccine:*

Refer to ACIP recommendation at:

[http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a4.htm?s\\_cid=mm5920a4\\_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a4.htm?s_cid=mm5920a4_e)

[If an ACIP recommendation regarding the human papillomavirus vaccination is published within 12 months following this resolution, the relevant language above (except in the eligible groups sections) will be replaced with the language in the recommendation and incorporated by reference to the publication URL.]

Adopted and Effective: October 25, 2011

This document can be found on the CDC website at:

<http://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/10-11-1-hpv.pdf>